ORIC Pharmaceuticals, Inc.

ORICNASDAQHealthcare● Active

$7.53

+$0.03(+0.40%)

Market Cap$779487242

P/E Ratio—

52W High$14.93

52W Low$7.23

Avg Volume1.9M

Open$7.63

Beta1.06

Free Cash Flow Financials Revenue

ORIC Pharmaceuticals, Inc. (ORIC) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ORIC · free cash flow · updated Jun 8, 2026

Core FCF metrics

ORIC · FCF · TTM · margin & CAGR

Free cash flow was −$114.1M for FY2025 (fiscal year ending 2025-12-31), down 0.2% year-over-year

FY2025 Free Cash Flow−$114.1M▼ -0.2% YoY

Trailing 12M (TTM)−$111.4Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ORIC · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$113.4M(1M)−$114.1M▼ 0.2%—

FY2024−$112.7M(1M)−$113.8M▼ 31.6%—

FY2023−$85.7M(1M)−$86.5M▼ 12.1%—

FY2022−$75.1M(2M)−$77.2M▼ 27.7%—

FY2021−$59.5M(1M)−$60.5M▼ 31.7%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ORIC · P/FCF · FCF yield · FCF per share

ORIC Pharmaceuticals, Inc. (ORIC) reported negative free cash flow of −$0.11B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ORIC · cash flow statement · operating / investing / financing

For FY2025, ORIC Pharmaceuticals, Inc. generated −$113.4M in operating cash flow and spent 1M in capital expenditures, yielding −$114.1M in free cash flow.

Operating Activities

−$113.4M

Cash from core business operations

2025-12-31

Investing Activities

−$148.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$247.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$113.4M) − |CapEx| (1M) = FCF (−$114.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ORIC vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ORIC Pharmaceuticals, Inc.YOU

ORIC

−$114.1M-0.2%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ORIC Pharmaceuticals, Inc. (ORIC) reported free cash flow of −$114.1M for FY2025 (fiscal year ending 2025-12-31), down 0.2% year-over-year.

ORIC Pharmaceuticals, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ORIC free cash flow · 8 questions

ORIC Pharmaceuticals, Inc. free cash flow was −$114.1M for FY2025, down 0.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$111.4M.

ORIC free cash flowORIC FCFORIC FCF 2025ORIC free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ORIC Pharmaceuticals, Inc. · ORIC Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026